George Magrath

This profile gathers the share dealings of George Magrath in Opus Genetics, Inc. Over a trading history stretching from 1 November 2023 to 9 September 2026, the count stands at 17 filings.

In open-market terms, that means 4 purchases worth €234k on one side and 3 sales worth €178k on the other. On balance, insiders were net buyers of €55k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 9 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 3 sales.

The median purchase comes to €66k. The 4 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The newest entry dates from 11 September 2026: an option exercise of €388k, in Opus Genetics, Inc. The last purchase on record was published on 30 December 2024, which is 657 days ago. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.